Receiver operating characteristic (ROC) to determine cut-off points of biomarkers in lung cancer patients

Disease Markers

Volumn 19, Issue 6, 2003, Pages 273-278

  Weiss, Heidi L ^a   Niwas, Santosh ^b   Grizzle, William E ^c   Piyathilake, Chandrika ^d  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b University of Alabama at Birmingham   (United States)

^c University of Alabama at Birmingham   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CANCER GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FATTY ACID SYNTHASE; PROTEIN P185; TRANSFORMING GROWTH FACTOR ALPHA;

AREA UNDER THE CURVE; ARTICLE; CALCULATION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG SENSITIVITY; DRUG SPECIFICITY; HUMAN; HUMAN TISSUE; LUNG CANCER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC;

EID: 3042760005     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.1155/2004/856026     Document Type: Article

References (19)

1. M.B. Sporn and G.J. Todaro, Autocrine growth factors and cancer, Nature 313 (1985), 745-751.
2. G.J. Kelloff, J.R. Johnson and J.A. Crowell et al., Approaches to the development and marketing approval of drugs that prevent cancer, Cancer Epidemiology, Biomarkers, and Prevention 4 (1995), 1-10.
3. K.A. Cronin, L.S. Freedman, R. Lieberman, H.L. Weiss, S.W. Beenken and G.J. Kelloff, Bayesian monitoring of phase II trials in cancer chemoprevention, J Clinical Epidemiology 52 8 (1999), 705-711.
4. A.S. Goustin, E.B. Leof, G.D. Shipley and H.L. Moses, Growth factors and cancer, Cancer Research 46 (1986), 1015-1029.
5. C.J. Piyathilake, A.R. Frost, U. Manne, H. Weiss, W.C. Bell, D.C. Heimburger and W.E. Grizzle, Differential expression of growth factors in squamous cell carcinoma and precancerous lesions of the lung, Clinical Cancer Research 8 (2002), 734-744.
6. F.J. Hendler and B.W. Ozanne, Human squamous cell lung cancers express increased epidermal growth factor receptors, J. Clin. Investig. 74 (1984), 647-651.
7. D. Veale, T. Ashcroft, C. Marsh, G.J. Gibson and A.L. Harris, Epidermal growth factor receptors in non-small cell lung cancer, Br. J. Cancer 55 (1987), 513-516.
8. V. Rusch, D. Klimstra, I. Linkov and E. Dmitrovsky, Aberrant expression of p53 or the epidermal growth factor receptor is frequent in early bronchial neoplasia and coexpression precedes squamous cell carcinoma development, Cancer Research 55 (1995), 1365-1372.
9. D. H. Harpole, J.R. Marks, W.G. Richards, J.E. Herndon and D.J. Sugarbaker, Localized adenocarcinoma of the lung: oncogene expression of erbB-2 and p53 in 150 patients, Clinical Cancer Research 1 (1995), 659-664.
10. P. Pfeiffer, P.P Clausen, K. Andersen and C. Rose, Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosections, Br. J. Cancer 74 (1996), 86-91.
11. V. Rusch, J. Baselga, C. Cordon-Cardo, J. Orazem, M. Zaman, S. Hoda, J. McIntosh, J. Kurie and E. Dmitrovsky, Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung, Cancer Research 53 (1993), 2379-2385.
12. V. Gorgoulis, D. Aninos, P. Mikou, P. Kanavaros, A. Karameris, J. Joardanoglou, A. Rasidakis, M. Veslemes, B. Ozanne and D.A. Spandidos, Expression of EGF, TGF- and EGFR in squamous cell lung carcinomas, Anticancer Research 12 (1992), 1183-1187.
13. T.C. Pina, I.T. Zapata, J.B. Lopez, J.L. Perez, P.P. Paricio and P.M. Hernandez, Tumor markers in lung cancer: Does the method of obtaining the cut-off point and reference population influence diagnostic yield? Clinical Biochemistry 32 6 (1999), 467-472.
14. B.C. Choi, Slopes of a Receiver Operating Characteristic Curve and Likelihood Ratios for a Diagnostic Test, American Journal of Epidemiology 148 (1998), 1127-1132.
15. W.E. Grizzle, R.B. Myers, U. Manne and S. Srivastava, Immunohistochemical evaluation of biomarkers in prostatic and colorectal neoplasia, in: John Walker's Methods in Molecular Medicine. Tumor Marker Protocols, M. Hanausek and Z. Walaszek, eds, Humana Press, Inc. Totowa, NJ, 1998, pp. 143-160.
16. W.C. Black and P. Armstrong, Communicating the significance of radiologic test results: the likelihood ratio, Am J. Roentgenol 147 (1986), 1313-1318.
17. A. Schatzkin, L.S. Freedman, M.H. Schiffman and S.M. Dawsey, Validation of Intermediate End Points in Cancer Research, Journal of the National Cancer Institute 82 22 (1990), 1746-1752.
18. C.J. Piyathilake, A.R. Frost, U. Manne, W.C. Bell, H. Weiss, D.C. Heimburger and W.E. Grizzle, The Expression of Fatty Acid Synthase (FASE) is an Early Event in the Development and Progression of Squamous Cell Carcinoma of the Lung, Human Pathol 31 (2000), 1068-1073.
19. M. Mazumdar and J.R. Glassman, Categorizing a prognostic variable: Review of methods, code for easy implementation and applications to decision-making about cancer treatments, Statistics in Medicine 19 (2000), 113-132.